NEW MJ NEWS

AYR Wellness Reports Third Quarter 2023 Results

AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator (“MSO”), is reporting financial results for the third quarter ended September 30, 2023. Unless otherwise noted, all results are presented in U.S. dollars.

The following financial measures are reported as results from continuing operations due to the sale of the Company’s business in Arizona in March 2023, which are reported as discontinued operations. All historical comparisons have been restated accordingly.

David Goubert, President & CEO of AYR, said, “We continued to execute on our optimization initiatives during the quarter, as reflected by another strong period of year-over-year adjusted EBITDA growth and cash flow generation. We also continued to lay the foundation for AYR’s long-term revenue growth and profitability, bolstered by our recent work to reach agreements with our creditors, which, when fully consummated, will result in the extension of maturities of nearly $400 million of debt in the aggregate by two years. Upon closing of the transactions, AYR will have no meaningful debt maturities until 2026 and an additional $40 million of cash proceeds, providing a clear runway to execute our optimization initiatives and generate consistent, long-term growth.

“As only 15 of the 88 dispensaries across our footprint are fully ramped adult-use stores, AYR is well-positioned to take advantage of legislative catalysts in states like Ohio, which voted just last week to legalize adult-use cannabis, as well as Florida and Pennsylvania in the near future. The conversion of these stores would reflect a 6x increase in our adult-use retail footprint.

“During the quarter, retail transactions were up 18% year-over-year on a same-store basis, largely driven by our initiatives to increase customer acquisition and loyalty. This increase was offset by continued pricing pressure in select markets, as well as temporary cultivation challenges in Florida over the summer, leading to lower inventory levels at the end of the quarter, which will further impact sales in the fourth quarter. We anticipate Florida inventory levels normalizing by mid-December.

“As we close out the year and look to 2024, we will continue to execute our optimization plan and lay the foundation for future revenue growth. I’m proud of the work the team has done to dramatically improve the financial health of AYR and we will remain focused on our liquidity and working capital as we further optimize inventory levels and align production with demand across our markets. We expect the execution of our objectives to position us for revenue growth, adjusted EBITDA margin expansion and free cash flow generation in 2024.”

Third Quarter Financial Summary (excludes results from AZ for all periods) ($ in millions, excl. margin items)

Q3 2022

Q2 2023

Q3 2023

% Change
Q3/Q3

% Change
Q3/Q2

Revenue

$108.7

$116.7

$114.4

5.2%

-2.0%

Gross Profit

$45.6

$56.6

$48.1

5.5%

-15.0%

Adjusted Gross Profit1

$57.5

$69.1

$60.5

5.2%

-12.4%

Operating Loss

$(19.5)

$(4.5)

$(1.5)

92.3%

66.7%

Adjusted EBITDA1

$18.7

$29.5

$28.4

51.9%

-3.7%

Adjusted EBITDA Margin1

17.2%

25.2%

24.9%

768bps

-37bps

1Adjusted EBITDA, Adjusted Gross Profit and Adjusted EBITDA Margin are non-GAAP measures, and accordingly are not standardized measures and may not be comparable to similar measures used by other companies. See Definition and Reconciliation of Non-GAAP Measures below. For a reconciliation of Operating Loss to Adjusted EBITDA as well as Gross Profit to Adjusted Gross Profit, see the reconciliation tables appended to this release.

Third Quarter Highlights

Announced agreement to acquire third Ohio dispensary license.

Reported Q3 retail transactions up 21% year-over-year on same-store basis.

Added Michael Warren to the Company’s Board of Directors.

Announced three-year exclusive licensing and retail agreement to bring Kiva Confections to AYR’s 62+ Florida dispensaries.

Changed expense allocation methodology resulting in an expense reclassification from SG&A to COGS that resulted in a 300bps reduction in adjusted gross margin in Q3.

Recent Highlights

Announced appointment of George DeNardo as new Chief Operating Officer.

Opened 10 Florida stores thus far in 2023, bringing its Florida store total to 62 open locations to date. The Company plans to exit 2023 with a total of 64 Florida stores, compared to 52 to start the year.

Opened two retail locations in Ohio in Woodmere and Goshen. AYR has the future rights to ownership of both dispensaries, subject to regulatory approval.

Last week, Ohio voters passed a ballot initiative to allow adult-use sales. AYR’s 58,000 square foot Ohio cultivation facility is operational and equipped to produce over 40 thousand pounds of biomass to meet future adult-use demand in the state.

Financing and Capital Structure

The Company deployed $7 million of capital expenditures in the third quarter and ended the quarter with a cash balance of $72.8 million.

The Company has approximately 76.7 million fully diluted shares outstanding based on a treasury method calculation.i

Subsequent to the quarter end, the Company announced that it had entered into agreements to extend the maturity date of its 12.5% senior notes and LivFree Wellness Promissory notes by two years and receive $40 million of new money debt financing. Additional terms and details of the transaction can be found in the Company’s press release announcing the transactions, dated November 1, 2023.

Upon completion of recently announced transactions in 2023, AYR will have retired or extended the maturity of nearly $400 million in debt in the aggregate by two years.

________________________
[i] Excludes AYR granted but unvested service-based LTIP shares totaling 5.0 million.

Outlook
The Company remains committed to further improving its financial health and positioning itself for sustainable, profitable growth across its footprint. Due to the modest sequential revenue decline in the third quarter, coupled with the temporary cultivation setback in Florida that will impact fourth quarter revenue by approximately $4-6 million, the Company no longer anticipates growth for the second half of 2023 over first half levels. The Company now expects revenue to be essentially flat in the fourth quarter compared to the third quarter, and to maintain an adjusted EBITDA margin of 25% in the fourth quarter.

AYR’s expectations for future results are based on the assumptions and risks detailed in its Management’s Discussion and Analysis (“MD&A”) for the period ended September 30, 2023, as filed on SEDAR+ and with the U.S. Securities and Exchange Commission (“SEC”).

Conference Call
AYR management will host a conference call today, followed by a question-and-answer period.

Date: Thursday, November 16, 2023
Time: 8:30 a.m. ET
Toll-free dial-in number: (800) 319-4610
International dial-in number: (604) 638-5340
Conference ID: 10022572

Please dial into the conference call 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact the Company’s investor relations team at ir@ayrwellness.com.

The conference will be broadcast live and available for replay here.

A telephonic replay of the conference call will also be available for one month until end of day Saturday, December 16, 2023.

Toll-free replay number: (855) 669-9658
International replay number: (412) 317-0088
Replay ID: 0479

Financial Statements
Certain financial information reported in this news release is extracted from AYR’s Consolidated Financial Statements and MD&A for the quarter ended September 30, 2023. AYR files its financial statements and MD&A on SEDAR+ and with the SEC. All financial information contained in this news release is qualified in its entirety by reference to such financial statements and MD&A.

Definition of GAAP
“GAAP” means United States generally accepted accounting principles.

Definition and Reconciliation of Non-GAAP Measures
The Company reports certain non-GAAP measures that are used to evaluate the performance of its businesses and the performance of their respective segments, as well as to manage their capital structures. As non-GAAP measures generally do not have a standardized meaning, they may not be comparable to similar measures presented by other issuers. Securities regulators require such measures to be clearly defined and reconciled with their most comparable GAAP measures.

Rather, these are provided as additional information to complement those GAAP measures by providing further understanding of the results of the operations of the Company from management’s perspective. Accordingly, these measures should not be considered in isolation, nor as a substitute for analysis of the Company’s financial information reported under GAAP. Non-GAAP measures used to analyze the performance of the Company’s businesses include “Adjusted EBITDA,” and “Adjusted Gross Profit.”

The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding the Company’s performances and may be useful to investors because they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making. These financial measures are intended to provide investors with supplemental measures of the Company’s operating performances and thus highlight trends in the Company’s core businesses that may not otherwise be apparent when solely relying on the GAAP measures.

Adjusted EBITDA
“Adjusted EBITDA” represents (loss) income from continuing operations, as reported under GAAP, before interest and tax, adjusted to exclude non-core costs, other non-cash items, including depreciation and amortization, and further adjusted to remove non-cash stock-based compensation, impairment expense, the incremental costs to acquire cannabis inventory in a business combination, acquisition and transaction related costs, and start-up costs.

Adjusted Gross Profit
“Adjusted Gross Profit” represents gross profit, as reported, adjusted to exclude the incremental costs to acquire cannabis inventory in a business combination, interest, depreciation and amortization, start-up costs and other non-core costs.

A reconciliation of how AYR calculates Adjusted EBITDA and Adjusted Gross Profit is provided in the tables appended below. Additional reconciliations of Adjusted EBITDA, Adjusted Gross Profit and other disclosures concerning non-GAAP measures are provided in our MD&A for the three months and nine months ended September 30, 2023.

Forward-Looking Statements
Certain statements are forward-looking statements within the meaning of applicable securities laws, including, but not limited to, those statements relating to the Company and its financial capacity and availability of capital and other statements that are not historical facts. These statements are based upon certain material factors, assumptions, and analyses that were applied in drawing a conclusion or making a forecast or projection, including experience of the Company, as applicable, and perception of historical trends, current conditions, and expected future developments, as well as other factors that are believed to be reasonable in the circumstances. Forward-looking statements are provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, ability to implement agreements reached with creditors to extend debt maturities, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, strategies, and outlook of the Company. Forward-looking statements are often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “project”, “expect”, “target”, “continue”, “forecast”, “design”, “goal” or negative versions thereof and other similar expressions.

Forward-looking estimates and assumptions involve known and unknown risks and uncertainties that may cause actual results to differ materially. While AYR believes there is a reasonable basis for these assumptions, such estimates may not be met. These estimates represent forward-looking information. Actual results may vary and differ materially from the estimates.

Assumptions and Risks
Forward-looking information in this release is subject to the assumptions and risks as described in our MD&A for the quarter ended September 30, 2023, and Annual Information Form as of and for the year ended December 31, 2022.

Additional Information
For more information about the Company’s third quarter and 2023 operations and outlook, please view AYR’s corporate presentation posted in the Investors section of the Company’s website at www.ayrwellness.com.

About AYR Wellness Inc.
AYR Wellness is a vertically integrated, U.S. multi-state cannabis business. The Company operates simultaneously as a retailer with 85+ licensed dispensaries and a house of cannabis CPG brands.

AYR is committed to delivering high-quality cannabis products to its patients and customers while acting as a Force for Good for its team members and the communities that the Company serves. For more information, please visit www.ayrwellness.com.

Company Contact:

Jon DeCourcey
Head of Investor Relations
T: (786) 885-0397
Email: ir@ayrwellness.com

Media Contact:

Robert Vanisko
VP, Public Engagement
T: (786) 885-0397
Email: comms@ayrwellness.com

Investor Relations Contact:

Sean Mansouri, CFA
Elevate IR
T: (786) 885-0397
Email: ir@ayrwellness.com

Ayr Wellness Inc.
Unaudited Interim Condensed Consolidated Balance Sheets
(Expressed in United States Dollars, in thousands, except share amounts)

As of

September 30, 2023

December 31, 2022

ASSETS

Current

Cash and cash equivalents

$

72,843

$

76,827

Accounts receivable, net

9,743

7,738

Inventory

98,485

99,810

Prepaid expenses, deposits, and other current assets

23,251

8,702

Assets held-for-sale

260,625

Total Current Assets

204,322

453,702

Non-current

Property, plant, and equipment, net

313,088

302,680

Intangible assets, net

702,581

744,709

Right-of-use assets – operating, net

122,080

121,340

Right-of-use assets – finance, net

41,801

43,222

Goodwill

94,108

94,108

Deposits and other assets

6,135

8,009

TOTAL ASSETS

$

1,484,115

$

1,767,770

LIABILITIES AND SHAREHOLDERS’ EQUITY

Liabilities

Current

Trade payables

21,698

26,671

Accrued liabilities

40,963

25,470

Lease liabilities – operating – current portion

9,132

7,906

Lease liabilities – finance – current portion

10,233

9,529

Contingent consideration – current portion

63,429

Purchase consideration payable

2,849

Income tax payable

77,707

46,006

Debts payable – current portion

59,052

40,523

Liabilities held-for-sale

43,841

Accrued interest payable – current portion

14,308

2,581

Total Current Liabilities

233,093

268,805

Non-current

Deferred tax liabilities, net

72,413

72,413

Lease liabilities – operating – non-current portion

119,455

118,086

Lease liabilities – finance – non-current portion

19,485

24,016

Construction finance liabilities

37,945

36,181

Contingent consideration – non-current portion

26,661

Debts payable – non-current portion

134,022

136,315

Senior secured notes, net of debt issuance costs

244,138

244,682

Accrued interest payable – non-current portion

4,763

Other long term liabilities

25,018

524

TOTAL LIABILITIES

885,569

932,446

Commitments and contingencies

Shareholders’ equity

Multiple Voting Shares – no par value, unlimited authorized. Issued and outstanding – 3,696,486 shares

Subordinate, Restricted, and Limited Voting Shares – no par value, unlimited authorized. Issued and outstanding – 63,882,257 and 60,909,492 shares, respectively

Exchangeable Shares: no par value, unlimited authorized. Issued and outstanding – 9,665,707 and 6,044,339 shares, respectively

Additional paid-in capital

1,367,532

1,349,713

Treasury stock – 645,300 shares

(8,987

)

(8,987

)

Accumulated other comprehensive income

3,266

3,266

Accumulated deficit

(754,450

)

(510,668

)

Equity of Ayr Wellness Inc.

607,361

833,324

Noncontrolling interest

(8,815

)

2,000

TOTAL SHAREHOLDERS’ EQUITY

598,546

835,324

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

$

1,484,115

$

1,767,770

Ayr Wellness Inc.
Unaudited Interim Condensed Consolidated Statements of Operations
(Expressed in United States Dollars, in thousands, except per share amounts)

Three Months Ended

Nine Months Ended

September 30, 2023

September 30, 2022

September 30, 2023

September 30, 2022

Revenues, net of discounts

$

114,392

$

108,739

$

348,795

$

307,156

Cost of goods sold excluding fair value items

66,261

62,670

195,735

178,984

Incremental costs to acquire cannabis inventory in business combinations

486

6,217

Cost of goods sold

66,261

63,156

195,735

185,201

Gross profit

48,131

45,583

153,060

121,955

Operating expenses

Selling, general, and administrative

38,833

50,594

137,813

147,415

Depreciation and amortization

11,909

11,676

39,390

33,791

Acquisition and transaction costs

(1,182

)

965

3,460

5,133

(Gain) loss on sale of assets

22

1,810

66

(190

)

Total operating expenses

49,582

65,045

180,729

186,149

Loss from continuing operations

(1,451

)

(19,462

)

(27,669

)

(64,194

)

Other income (expense), net

Fair value gain on financial liabilities

1,658

23,731

33,438

Interest expense, net

(10,772

)

(7,271

)

(28,834

)

(20,491

)

Interest income

193

12

591

52

Other income, net

6,303

13

6,934

13

Total other income (expense), net

(4,276

)

(5,588

)

2,422

13,012

Loss from continuing operations before income taxes and noncontrolling interest

(5,727

)

(25,050

)

(25,247

)

(51,182

)

Income taxes

Current tax provision

(13,543

)

(11,059

)

(37,608

)

(30,306

)

Deferred tax benefit

1,433

2,129

Total income taxes

(13,543

)

(9,626

)

(37,608

)

(28,177

)

Net loss from continuing operations

(19,270

)

(34,676

)

(62,855

)

(79,359

)

Discontinued operations

Loss from discontinued operations, net of taxes (including loss on disposal of $181,191 for the nine months ended September 30, 2023)

(996

)

(2,751

)

(185,683

)

(7,510

)

Loss from discontinued operations

(996

)

(2,751

)

(185,683

)

(7,510

)

Net loss

(20,266

)

(37,427

)

(248,538

)

(86,869

)

Net loss attributable to noncontrolling interest

(1,020

)

(1,310

)

(4,756

)

(4,818

)

Net loss attributable to Ayr Wellness Inc.

$

(19,246

)

$

(36,117

)

$

(243,782

)

$

(82,051

)

Basic and diluted net loss per share

Continuing operations

$

(0.24

)

$

(0.48

)

$

(0.79

)

$

(1.09

)

Discontinued operations

(0.01

)

(0.04

)

(2.54

)

(0.11

)

Total (basic and diluted) net loss per share

$

(0.25

)

$

(0.52

)

$

(3.33

)

$

(1.20

)

Weighted average number of shares outstanding (basic and diluted)

76,563

68,948

73,105

68,391

Ayr Wellness Inc.
Unaudited Interim Condensed Consolidated Statements of Cash Flows
(Expressed in United States Dollars, in thousands)

Nine Months Ended

September 30, 2023

September 30, 2022

Operating activities

Consolidated net loss

$

(248,538

)

$

(86,869

)

Less: Loss from discontinued operations

(4,492

)

(7,510

)

Net loss from continuing operations before noncontrolling interest

(244,046

)

(79,359

)

Adjustments for:

Fair value gain on financial liabilities

(23,731

)

(33,438

)

Stock-based compensation

13,338

28,652

Stock-based compensation – related parties

707

Shares issued for consulting services

79

Depreciation and amortization

24,984

12,417

Amortization on intangible assets

43,828

42,660

Incremental costs to acquire cannabis inventory in a business combination

6,217

Deferred tax benefit

(2,128

)

Amortization on financing costs

1,743

1,719

Amortization on financing premium

(2,263

)

(2,263

)

Employee Retention Credits recorded in other income

(5,238

)

Loss (gain) on disposal of property, plant, and equipment

66

(190

)

Loss on the disposal of Arizona business

181,191

Changes in operating assets and liabilities, net of business combinations:

Accounts receivable

(2,305

)

278

Inventory

1,626

(10,304

)

Prepaid expenses, deposits, and other current assets

(4,164

)

824

Trade payables

(5,334

)

(4,318

)

Accrued liabilities

3,245

(1,473

)

Accrued interest payable

6,653

3,547

Lease liabilities – operating

1,857

1,524

Income tax payable

31,396

3,833

Cash provided by (used in) continuing operations

22,925

(31,095

)

Cash provided by (used in) discontinued operations

2,180

(3,608

)

Cash provided by (used in) operating activities

25,105

(34,703

)

Investing activities

Purchase of property, plant, and equipment

(20,790

)

(55,294

)

Capitalized interest

(7,274

)

(10,552

)

Cash paid for business combinations and asset acquisitions, net of cash acquired

(1,500

)

(11,469

)

Cash paid for business combinations and asset acquisitions, working capital

(2,600

)

(2,812

)

Proceeds from the sale of assets, net of transaction costs

31,433

Cash received (paid) for bridge financing

(72

)

1,070

Advances to related entities

(7,005

)

Deposits for business combinations, net of cash on hand

(2,825

)

Purchase of intangible asset

(1,700

)

(4,000

)

Cash used in investing activities from continuing operations

(33,936

)

(61,454

)

Proceeds from sale of Arizona – discontinued operation

18,084

Cash received for working capital – discontinued operations

840

Cash provided by (used in) investing activities of discontinued operations

(44

)

3,145

Cash used in investing activities

(15,056

)

(58,309

)

Financing activities

Proceeds from exercise of options

300

Proceeds from notes payable, net of financing costs

10,430

51,713

Proceeds from financing transaction, net of financing costs

39,100

27,599

Payment for settlement of contingent consideration

(10,118

)

(10,000

)

Deposits paid for financing lease and note payable

(924

)

Tax withholding on stock-based compensation awards

(360

)

(4,738

)

Repayments of debts payable

(49,098

)

(8,257

)

Repayments of lease liabilities – finance (principal portion)

(7,676

)

(7,438

)

Repurchase of Equity Shares

(8,430

)

Cash provided by (used in) financing activities by continuing operations

(17,722

)

39,825

Cash used in financing activities from discontinued operations

(124

)

(393

)

Cash provided by (used in) financing activities

(17,846

)

39,432

Net decrease in cash and cash equivalents and restricted cash

(7,797

)

(53,580

)

Cash, cash equivalents and restricted cash beginning of the period

76,827

154,342

Cash included in assets held-for-sale

3,813

Cash, cash equivalents and restricted cash end of the period

$

72,843

$

100,762

Supplemental disclosure of cash flow information:

Interest paid during the period, net

$

25,430

$

30,747

Income taxes paid during the period

7,080

29,248

Non-cash investing and financing activities:

Recognition of right-of-use assets for operating leases

8,586

52,296

Recognition of right-of-use assets for finance leases

4,402

30,812

Issuance of promissory note related to business combinations

1,580

16,000

Conversion of convertible note related to business combination

2,800

Issuance of Equity Shares related to business combinations and asset acquisitions

115

6,352

Issuance of Equity Shares related to settlement of contingent consideration

4,647

11,748

Issuance of promissory note related to settlement of contingent consideration

14,000

14,934

Settlement of contingent consideration

37,713

Capital expenditure disbursements for cultivation facility

1,764

7,837

Cancellation of Equity Shares

78

Extinguishment of note payable related to sale of Arizona business

22,505

Extinguishment of accrued interest payable related to sale of Arizona business

1,165

Reduction of lease liabilities related to sale of Arizona business

16,734

Reduction of right-of-use assets related to sale of Arizona business

16,739

Ayr Wellness Inc.
Unaudited Interim Consolidated Adjusted EBITDA and Gross Profit Reconciliation
(Expressed in United States Dollars, in thousands)

Three Months Ended

Nine Months Ended

September 30, 2023

September 30, 2022

September 30, 2023

September 30, 2022

$

$

$

$

Loss from continuing operations (GAAP)

(1,451

)

(19,462

)

(27,669

)

(64,194

)

Incremental costs to acquire cannabis inventory in a business combination

486

6,217

Interest (within cost of goods sold “COGS”)

776

1,694

2,290

2,898

Depreciation and amortization (from statement of cash flows)

22,019

19,549

68,812

55,077

Acquisition and transaction costs

(1,182

)

965

3,460

5,133

Stock-based compensation, non-cash

3,410

9,359

13,417

29,447

Start-up costs1

2,909

2,930

8,871

10,037

(Gain) loss on sale of assets

22

1,810

66

(190

)

Other2

1,924

1,337

14,961

6,802

29,878

38,130

111,877

115,421

Adjusted EBITDA from continuing operations (non-GAAP)

28,427

18,668

84,208

51,227

1 These are set-up costs to prepare a location for its intended use. Start-up costs are expensed as incurred and are not indicative of ongoing operations

2 Other non-core costs including non-operating adjustments, severance costs and non-cash inventory write-downs

Three Months Ended

Nine Months Ended

September 30, 2023

September 30, 2022

September 30, 2023

September 30, 2022

$

$

$

$

Gross profit (GAAP)

48,131

45,583

153,060

121,955

Incremental costs to acquire cannabis inventory in a business combination

486

6,217

Interest (within COGS)

776

1,694

2,290

2,898

Depreciation and amortization (within COGS)

10,109

7,873

29,422

21,286

Start-up costs (within COGS)

1,295

1,020

4,305

3,772

Other (within COGS)

196

830

5,773

4,883

Adjusted Gross Profit from continuing operations (non-GAAP)

60,507

57,486

194,850

161,011


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Canopy Growth Corporation (CGC) Reports Second Quarter Fiscal 2022 Financial Results

Canopy Growth Reports Second Quarter Fiscal 2022 Financial Results Canopy Growth Corporation…

Tetra Bio-Pharma Inc. (TBPMF) Signs Definitive Agreement for Two Products

Tetra Bio-Pharma Signs Definitive Agreement for Two Products with Panag Pharma Tetra…

EAPH Income Statement

Easton Pharmaceuticals Inc. (EAPH)   Income Statement Get Income Statement for: View:…

$MDBX To Be Investigated by Harwood Feffer LLP

Harwood Feffer LLP Announces Investigation of Medbox, Inc. NEW YORK, Dec. 30,…